Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 31 articles:
HTML format
Text format



Single Articles


    January 2017
  1. SORIA JC, Tan DS, Chiari R, Wu YL, et al
    First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30123.
    PubMed     Text format     Abstract available


  2. SOLOMON B
    First-line treatment options for ALK-rearranged lung cancer.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30124.
    PubMed     Text format    


    December 2016
  3. LEDUC C, Quoix E
    Programmed death of chemotherapy in non-small-cell lung cancer?
    Lancet. 2016 Dec 12. pii: S0140-6736(16)32535.
    PubMed     Text format    


  4. RITTMEYER A, Barlesi F, Waterkamp D, Park K, et al
    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
    Lancet. 2016 Dec 12. pii: S0140-6736(16)32517.
    PubMed     Text format     Abstract available


    October 2016
  5. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    PubMed     Text format     Abstract available


  6. ZHANG L, Huang Y, Hong S, Yang Y, et al
    Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Lancet. 2016;388:1883-1892.
    PubMed     Text format     Abstract available


    September 2016
  7. SCHILDGEN V, Schildgen O
    Routine molecular profiling of patients with NSCLC.
    Lancet. 2016;388:1054.
    PubMed     Text format    


  8. HIRSCH FR, Suda K, Wiens J, Bunn PA Jr, et al
    New and emerging targeted treatments in advanced non-small-cell lung cancer.
    Lancet. 2016;388:1012-24.
    PubMed     Text format     Abstract available


  9. HILEY CT, Le Quesne J, Santis G, Sharpe R, et al
    Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.
    Lancet. 2016;388:1002-11.
    PubMed     Text format     Abstract available


  10. MULVENNA P, Nankivell M, Barton R, Faivre-Finn C, et al
    Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiori
    Lancet. 2016 Sep 2. pii: S0140-6736(16)30825.
    PubMed     Text format     Abstract available


    August 2016
  11. HIRSCH FR, Scagliotti GV, Mulshine JL, Kwon R, et al
    Lung cancer: current therapies and new targeted treatments.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)30958.
    PubMed     Text format     Abstract available


  12. THE LANCET
    Lung cancer: despite advances, prevention is still best.
    Lancet. 2016;388:533.
    PubMed     Text format    


    July 2016
  13. YAO JC, Voi M, Rouyrre N, Singh S, et al
    Everolimus in ileum neuroendocrine tumours - Authors' reply.
    Lancet. 2016;388:236-7.
    PubMed     Text format    


  14. WALTER T, Lombard-Bohas C
    Everolimus in ileum neuroendocrine tumours.
    Lancet. 2016;388:236.
    PubMed     Text format    


    May 2016
  15. RUSSELL P, Floridis J
    Hypertrichosis lanuginosa acquisita: a rare dermatological disorder.
    Lancet. 2016;387:2035.
    PubMed     Text format    


    April 2016
  16. HORNLUND A
    Clarification regarding ethical review of Paolo Macchiarini's research.
    Lancet. 2016;387:1816.
    PubMed     Text format    



  17. Expression of concern--Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.
    Lancet. 2016;387:1359.
    PubMed     Text format    


    March 2016
  18. SMIT EF, van den Heuvel MM
    PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
    Lancet. 2016 Mar 10. pii: S0140-6736(16)00700.
    PubMed     Text format    


  19. FEHRENBACHER L, Spira A, Ballinger M, Kowanetz M, et al
    Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Lancet. 2016 Mar 9. pii: S0140-6736(16)00587.
    PubMed     Text format     Abstract available


  20. CLAESSON-WELSH L, Hansson GK
    Tracheobronchial transplantation: The Royal Swedish Academy of Sciences' concerns.
    Lancet. 2016;387:942.
    PubMed     Text format    


  21. YAO JC, Fazio N, Singh S, Buzzoni R, et al
    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
    Lancet. 2016;387:968-77.
    PubMed     Text format     Abstract available


  22. OBERG K
    Universal everolimus for malignant neuroendocrine tumours?
    Lancet. 2016;387:924-6.
    PubMed     Text format    


    January 2016
  23. MACCHIARINI P
    Tracheobronchial transplantation.
    Lancet. 2016;387:339.
    PubMed     Text format    


  24. ROSELL R, Karachaliou N
    Large-scale screening for somatic mutations in lung cancer.
    Lancet. 2016 Jan 14. pii: S0140-6736(15)01125.
    PubMed     Text format    


  25. BARLESI F, Mazieres J, Merlio JP, Debieuvre D, et al
    Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
    Lancet. 2016 Jan 14. pii: S0140-6736(16)00004.
    PubMed     Text format     Abstract available


    December 2015
  26. MOK TS, Loong HH
    Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
    Lancet. 2015 Dec 18. pii: S0140-6736(15)01308.
    PubMed     Text format    


  27. HERBST RS, Baas P, Kim DW, Felip E, et al
    Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Lancet. 2015 Dec 18. pii: S0140-6736(15)01281.
    PubMed     Text format     Abstract available


    August 2015
  28. JAYAKRISHNAN B, Dildar B, Rizavi DM, Al Mubaihsi SM, et al
    Black pleural effusion.
    Lancet. 2015;386:e7.
    PubMed     Text format    


  29. PLESS M, Stupp R, Ris HB, Stahel RA, et al
    Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Lancet. 2015 Aug 11. pii: S0140-6736(15)60294.
    PubMed     Text format     Abstract available


  30. EBERHARDT WE, Stuschke M
    Multimodal treatment of non-small-cell lung cancer.
    Lancet. 2015 Aug 11. pii: S0140-6736(15)61083.
    PubMed     Text format    


    June 2015
  31. AMMIRATI E, Stucchi M, Brambatti M, Spano F, et al
    Eosinophilic myocarditis: a paraneoplastic event.
    Lancet. 2015;385:2546.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: